The company's growth from DNA2.0 to ATUM has evolved with the science, and has been particularly catalyzed by:
- James Love, Ph.D., joining the company in 2015 to develop and lead protein expression services.
- The acquisition of MIGS, the antibody engineering powerhouse founded by Michael Feldhaus, Ph.D., who joined the company's executive team in April 2016.
- The recent hiring of Ferenc Boldog, Ph.D., who brings decades of pharmaceutical industry experience to establish ATUM's cell line development offerings.
- The issuance of the first patents in an emerging LeapIn transposase portfolio. This tool has applications in gene expression, gene therapy and gene discovery, as well as ATUM's cell line service.
"Historically, we have partnered with companies who use our DNA-based tools in-house," said Dr. Minshull. "By optimizing the interactions between our molecular tools, cells and growth conditions, we can offer more complete solutions, and speed our partners' progress. For example, we provide antibody engineering and upstream services to support the search for tomorrow's drugs, to abate climate change and to solve the problem of food insecurity."
ATUM, formerly DNA2.0, offers an integrated pipeline of tools including gene design, optimization and synthesis, expression vectors, and platforms for protein and strain engineering and production. ATUM exploits the dependence of biological activity on well-designed sequences. ATUM's tools and solutions are fueling the transformation of biology from a discovery science to an engineering discipline. By collaborating with clients, ATUM accelerates breakthroughs and moves research further faster. The company is privately held and is headquartered in Newark, California. For more information, please visit http://www.atum.bio.
Lisa Lilienthal, 404-661-3679
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/dna20-inc-becomes-atum-300376599.html